Adage Capital Partners’s Aevi Genomic Medicine Inc GNMX Stock Holding History

Adage Capital Partners’s Portfolio GNMX Stock Details GNMX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q1	–	Sell	-5,500,000	Closed	-$3.85M	–	755
2018 Q4	$3.85M	Hold	5,500,000	–	–	0.01%	630
2018 Q3	$6.76M	Hold	5,500,000	–	–	0.02%	602
2018 Q2	$6.11M	Hold	5,500,000	–	–	0.01%	637
2018 Q1	$11.1M	Hold	5,500,000	–	–	0.03%	537
2017 Q4	$6.6M	Buy	5,500,000 +3,400,000	+162%	+$4.64M	0.01%	608
2017 Q3	$2.65M	Hold	2,100,000	–	–	0.01%	663
2017 Q2	$2.79M	Buy	2,100,000 +1,000,000	+91%	+$1.45M	0.01%	656
2017 Q1	$2.05M	Sell	1,100,000 -1,000,000	-48%	-$4.52M	0.01%	662
2016 Q4	$10.9M	Hold	2,100,000	–	–	0.03%	517
2016 Q3	$11.7M	Hold	2,100,000	–	–	0.03%	492
2016 Q2	$11.7M	Buy	2,100,000 +850,000	+68%	+$4.46M	0.03%	483
2016 Q1	$5.5M	Buy	1,250,000 +350,000	+39%	+$1.44M	0.01%	597
2015 Q4	$5.42M	Buy	+900,000	New	+$6.11M	0.01%	596

Other funds holding GNMX

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Virtu Financial New York $3.18B AUM 65.92% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

Bridgeway Capital Management Houston, Texas $5.69B AUM 60.64% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Birchview Capital Burlington, Vermont $214M AUM 185.33% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Adage Capital Partners's GNMX Position: Q1 2019 in Review

Adage Capital Partners sold out of Aevi Genomic Medicine Inc (GNMX) in Q1 2019, closing a stake of 5,500,000 shares — an estimated $3.85M sold.

Adage Capital Partners first reported a position in GNMX in Q4 2015 and held it in 13 quarters. The position peaked at $11.7M in Q3 2016. 28 funds tracked by Wall St. Rank hold GNMX as of Q1 2019.

Adage Capital Partners reported no remaining Aevi Genomic Medicine Inc position as of Q1 2019 after selling out during the quarter.
Adage Capital Partners sold 5,500,000 Aevi Genomic Medicine Inc shares in Q1 2019, an estimated $3.85M.
Adage Capital Partners first reported a position in Aevi Genomic Medicine Inc in Q4 2015 and held it in 13 quarters.
Adage Capital Partners's Aevi Genomic Medicine Inc position peaked at $11.7M in Q3 2016.
28 funds tracked by Wall St. Rank held Aevi Genomic Medicine Inc as of Q1 2019.

Based on Adage Capital Partners's 13F filing for Q1 2019, filed 15 May 2019.